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ABSTRACT
A 1-year retrospective multicentre study was performed to identify factors inﬂuencing hospital length of
stay (LOS) and mortality of patients (n = 3233) admitted to hospital because of community-acquired
pneumonia (CAP). Pneumonia severity index (PSI) high-risk classes (IV and V), positive blood culture,
admission to an intensive care unit (ICU), multi-lobar involvement and alcohol consumption were
associated independently with prolonged LOS. Tobacco smoking was associated with a reduced LOS.
The LOS varied markedly among centres. Only PSI high-risk class, admission to ICU and multi-lobar
involvement were associated with early, late and global mortality. Positive blood cultures, antimicrobial
therapy according to treatment guidelines and the establishment of an aetiological diagnosis were linked
to reduced late and global mortality. These data suggest that early mortality associated with CAP is
highly dependent on the clinical status of the patient at presentation. Conversely, late mortality seems to
be associated more closely with clinical management factors; hence, an aetiological diagnosis and
compliance with appropriate therapeutic guidelines have a signiﬁcant inﬂuence on outcome.
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INTRODUCTION
Community-acquired pneumonia (CAP) remains
a signiﬁcant cause of hospital admission and
death. Mortality rates have stabilised at c. 12%
since 1950, despite advances in knowledge of this
illness, improvements in the management of
severe infectious diseases, the availability of
intensive care, and the use of potent antimicrobial
agents and effective vaccines [1,2]. Although there
are a large number of international guidelines and
recommendations concerning the management of
CAP, there are also wide variations among
centres and clinicians concerning reasons for
admission, microbiological testing and therapy,
which suggests that physicians do not follow
these recommendations uniformly. This is impor-
tant, since some studies have shown that compli-
ance with guidelines and ⁄ or treatment
recommendations is associated with lower mor-
tality in patients with CAP [3–5].
Besides treatment, other factors related to
patient characteristics and ⁄ or clinical practice
have been associated with a poor prognosis and
mortality. With some of these factors, several
scoring systems have been developed to aid
physicians in the assessment of the severity of
illness, which should always be used in associa-
tion with good clinical judgement [6,7]. Fine et al.
[8] identiﬁed several risk-factors that were asso-
ciated independently with mortality, including
demographical factors, co-morbidities, ﬁndings
from the initial physical examination, and labo-
ratory and radiographical ﬁndings at the initial
examination, from which a predictive outcome
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rule, based on a pneumonia severity index (PSI),
was developed. This 20-variable rule categorised
patients into ﬁve risk classes, according to their
30-day risk of death, ranging from 0.1% for class I
to 27% for class V. In addition to the PSI, other
scoring systems, e.g., the ﬁve-variable CURB65
and the CRB65 systems (without the requirement
for laboratory investigations), have also been
shown to be useful tools in predicting the severity
of CAP [9].
Although many factors related to a patient’s
characteristics cannot be modiﬁed, some factors
related to clinical practices can be addressed.
Therefore, the identiﬁcation of factors inﬂuencing
mortality, especially those factors related to
clinical management that could be modiﬁed,
should remain a priority. The aim of the present
study was to identify factors inﬂuencing hospital
length of stay (LOS) and overall, early and late
mortality in patients admitted to hospital because
of CAP.
MATERIALS AND METHODS
Study subjects
Patients were identiﬁed using the International Classiﬁcation of
Diseases, 9th revision (ICD-9), for discharge diagnoses consis-
tent with CAP: a primary or secondary discharge diagnosis of
pneumonia (codes 480.0–483.99 and 485–487.0). To ensure the
accuracy of this CAP diagnosis, one or two physicians at each
centre, who were specially trained for this study, reviewed the
medical records of every potentially eligible patient to ascertain
the presence of: (i) a new inﬁltrate on a chest radiograph,
compatible with pneumonia and not attributable to another
cause, and (ii) an acute onset of signs and symptoms that were
suggestive of a lower respiratory tract infection. Patients aged
<18 years, those discharged from any hospital in the 14-day
period before the current admission or who were transferred
from another hospital, those previously discharged directly
from the emergency room or transferred to another hospital
before the resolution of the episode, or those who had a
diagnosis of tuberculosis, were excluded.
Study design
This was a retrospective, multicentre study of patients with
CAP who required hospital admission during a 1-year period
in ten Spanish university tertiary-care hospitals. All patients
admitted to hospital because of CAP between 1 November
2001 and 31 October 2002 were included in the study, and their
data were recorded on a standardised case report form. All
forms were checked thoroughly by independent reviewers for
the accuracy of the data. This audit-like methodology ensured
that no data were missed. Clinical information was obtained
from the medical charts. Microbiological data were obtained
from medical charts and ⁄or laboratory records. All study data
were identiﬁed by study subject number and were double-
entered into a computerised database. Accuracy of data entry
was veriﬁed and discrepancies were corrected by reference to
the primary record.
As recommended by the International Guidelines for
Ethical Review of Epidemiological Studies (http://www.ci-
oms.ch/frame_guidelines_nov_2002), this study was ap-
proved by the Research Ethics Committee of the Hospital
Mu´tua de Terrassa, Barcelona, Spain.
Analysis
LOS was deﬁned as the time (days) spent in hospital. Excess
LOS was deﬁned as the number of days (upper limit of the
corresponding 95% CI hazard ratio) over the mean LOS. Early
mortality was deﬁned as death from any cause within 2 days
of hospital admission, and late mortality as death >2 days after
admission. Overall mortality was deﬁned as death from any
cause during the hospitalisation period. Pneumonia severity
upon hospital admission was estimated using the validated
prediction rule, calculated according to the PSI scores,
developed by the Pneumonia Outcomes Research Team, as
described previously [8].
An aetiological diagnosis was considered positive (deﬁni-
tive or presumptive) in the following situations: isolation of a
respiratory pathogen from a normally sterile specimen; isola-
tion of a respiratory pathogen from a protected specimen
brush or bronchoalveolar lavage ﬂuid (bacterial growth of ‡103
or ‡104 CFU ⁄mL, respectively); isolation of Legionella pneumo-
phila from sputum samples; a serological test with paired
serum samples revealing a four-fold increase in antibody
levels; urinary antigen tests positive for L. pneumophila or
Streptococcus pneumoniae; and isolation of a predominant
microorganism from a validated sputum, bronchial aspirate
or tracheobronchial aspirate. Patients for whom no microbio-
logical tests were performed, and patients with negative
microbiogical results, were considered to have disease of an
unknown aetiology.
For themultivariate analysis, antibiotic regimens considered
to be appropriate by the Infectious Diseases Society of Amer-
ica ⁄American Thoracic Society (IDSA ⁄ATS) included the use of
a b-lactam in combination with a macrolide or a respiratory
ﬂuoroquinolone, or a respiratory ﬂuoroquinolone alone at
admission [2,10]. The use of either a b-lactam or a macrolide in
monotherapy was considered to be inappropriate.
Univariate associations for proportions were performed
using a two-sided Pearson correlation coefﬁcient. Univariate
analysis of LOS was performed using the Kaplan–Meier
method. Independent prognostic factors for LOS were identi-
ﬁed by a stepwise forward Cox regression model, in which all
covariates of the univariate analyses were entered. For analysis
of mortality, variables were analysed using a forward logistic
regression model that included all the variables tested in
univariate analyses. A two-sided p value <0.05 was considered
to be signiﬁcant in all analyses. The statistical analyses were
performed using SPSS v.15.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
In total, 3233 subjects with CAP who were
admitted to the study hospitals met the inclusion
criteria. The mean age was 66.6 ± 18.5 years
(range 18–100 years) and 63.8% of the patients
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were male. Table 1 shows patient outcomes,
grouped according to PSI categories. With the
exception of the establishment of an aetiological
diagnosis, the variables in Table 1 were more
frequent in patients in high-risk classes (IV and
V). LOS was longer for patients in high-risk
classes (IV and V) than it was for patients in low-
risk classes (I–III). The proportion of patients
belonging to each PSI class also varied widely
among hospitals, as did the proportion of patients
with an aetiological diagnosis, the LOS and the
mortality rate (Table 2).
Presumptive or deﬁnitive diagnoses were
established for 23.6% (762 ⁄ 3233) of the patients.
The pathogens identiﬁed most frequently were
S. pneumoniae (n = 425, 13.1%), L. pneumophila
(n = 68, 2.1%), Haemophilus inﬂuenzae (n = 46,
1.4%) and Mycoplasma pneumoniae (n = 38, 1.2%).
Signiﬁcant differences in the diagnostic tech-
niques used were found between patients who
died and those who survived in terms of the
proportion of sputum samples cultured (40.0%
vs. 18.6%), blood samples cultured (48.4% vs.
41.4%), Legionella urinary antigen tests (39.0% vs.
18.9%) and S. pneumoniae urinary antigen tests
(31.6% vs. 14.3%) administered and other respi-
ratory samples cultured (8.7% vs. 13.9%). Paired
serological tests and culture of sputum samples
were the diagnostic techniques yielding the high-
est rate of positive results (60.6% and 38.6%,
respectively; Table 3).
Overall, 22.5% (63 ⁄ 280) of the patients who
died had received antibiotics before presentation
to the emergency department. This percentage
was similar to that for patients who survived
(25.1%; 741 ⁄ 2953). No differences among the
antibiotics administered were found between the
two groups. The most frequent antibiotics admin-
istered before presentation to the emergency
department were penicillins (279 patients), mac-
rolides (199 patients), quinolones (182 patients)
and cephalosporins (128 patients).
Analyses of outcomes
LOSwas assessed for all patients except those who
died in hospital. Mean LOS was 11.5 days (range
1–111 days), with a median of 9 days (inter-quar-
tile range, 7–14 days). Table 4 shows the mean
and median LOS analysed for each variable,
Table 1. Outcomes grouped accord-
ing to pneumonia severity index
(PSI) risk classOutcome measure
Patients in PSI risk class (%)a
I II III IV V Total
Patients 403 (12.5) 492 (15.2) 711 (22.0) 1145 (35.4) 482 (14.9) 3233 (100)
Admission to the ICU 10 (2.5) 18 (3.7) 28 (3.9) 57 (5.0) 49 (10.2) 162 (5.0)
Mechanical ventilation 6 (1.5) 6 (1.2) 20 (3.8) 40 (3.5) 28 (5.8) 100 (3.1)
Aetiological diagnosis 118 (29.3) 123 (25.0) 174 (24.5) 252 (22.0) 95 (19.7) 762 (23.6)
LOS, mean days 8.6 9.4 11.2 13.0 14.4 11.5
Early deathb 0 1 (0.2) 2 (0.3) 15 (1.3) 36 (7.5) 54 (1.7)
Late deathc 2 (0.5) 10 (2.0) 18 (2.5) 98 (8.6) 98 (20.3) 226 (7.0)
Total deaths 2 (0.5) 11 (2.2) 20 (3.8) 113 (9.9) 134 (27.8) 280 (8.7)
LOS, length of stay (calculated excluding patients who died or were discharged home); ICU, intensive care unit.
aData are numbers of patients (%), unless otherwise indicated.
bDied £48 h after admission to the hospital.
cDied >48 h after admission to the hospital.
Table 2. Characteristics and outcomes of study population grouped according to site of care
Characteristics
Sitesa
Total
(n = 3233) p value1 (n = 410) 2 (n = 712) 3 (n = 231) 4 (n = 235) 5 (n = 255) 6 (n = 376) 7 (n = 187) 8 (n = 336) 9 (n = 288) 10 (n = 203)
PSI risk class
Low-riskb 164 (40) 392 (55) 90 (39) 125 (53) 122 (48) 190 (51) 108 (58) 214 (64) 112 (39) 89 (44) 1606
High-riskc 246 (60) 320 (45) 141 (61) 110 (47) 133 (52) 186 (49) 79 (42) 122 (36) 176 (61) 114 (56) 1627 <0.001
Aetiological
diagnosis
30 (7) 297 (42) 73(32) 48 (20) 43 (17) 61 (16) 44 (24) 93 (28) 43 (15) 30 (15) 762 <0.001
LOS (days) 10.8 ± 6.5 11.0 ± 7.5 9.2 ± 5.3 11.1 ± 7.5 14.7 ± 8.1 13.3 ± 8.3 10.0 ± 5.8 7.8 ± 7.4 12.8 ± 7.6 17.3 ± 16.3 11.5 ± 8.4 <0.001
Deaths 45 (11.0) 59 (8.3) 10 (4.3) 19 (8.1) 34 (13.3) 35 (9.3) 2 (1.1) 7 (2.1) 29 (10.1) 40 (19.7) 280 (8.7) <0.001
PSI, pneumonia severity index risk class; LOS, length of stay (calculated excluding patients who died or were discharged home).
aData are presented as n (%) or mean ± SD unless otherwise indicated.
bPSI classes I–III.
cPSI classes IV and V.
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together with the univariate Kaplan–Meier p va-
lue and the results of the multivariate Cox regres-
sion (hazard risk, 95% CI and p value). A PSI
high-risk classiﬁcation (classes IV–V), admission
to an intensive care unit (ICU), multi-lobar pneu-
monia and regular consumption of alcohol were
associated independently with a more prolonged
LOS in the multivariate Cox regression analysis.
Excess LOS was 7.0 days for patients in a high-risk
class, 19.9 days if admitted to an ICU, 4.4 days if
there was multi-lobar involvement, and 6.3 if the
patient consumed alcohol regularly. In contrast,
being an active smoker of tobacco was associated
with a reduced LOS.
Overall, 280 patients died (8.7% mortality)
during hospitalisation. By day 30, there were 269
deaths, i.e., 96.0% of the total mortality of the
series (Fig. 1). Several variables showed an asso-
ciation with mortality in the univariate analysis
(Table 5). For early mortality, the multivariate
analysis indicated that only high-risk PSI classes
(IV and V), admission to an ICU and multi-lobar
involvement were associated directly with excess
mortality. For late mortality, high-risk PSI classes,
positive blood cultures, admission to an ICU and
multi-lobar involvement were associated with
higher mortality. More importantly, following
IDSA ⁄ATS recommendations for empirical treat-
ment of CAP and establishing the aetiology of the
CAP episode were both associated with reduced
late and overall mortality. Active use of tobacco
was also linked to reduced mortality.
Table 3. Diagnostic techniques used, showing the association between mortality and the number of positive results
(n = 3233)
Mortality (%)
No. of patients with procedures
performed ⁄no. with positive resultsNo (n = 2953) Yes (n = 280) p value
Gram’s stain of sputum sample 987 (33.4) 50 (17.9) <0.001 1037 ⁄ 429
Culture of sputum sample 1179 (40.0) 52 (18.6) <0.001 1231 ⁄ 475
Culture of blood sample pre-antibiotic treatment 1429 (48.4) 116 (41.4) 0.02 1545 ⁄ 174
Paired serological testa 203 – – 203 ⁄ 123
Legionella urinary antigen detection 1152 (39.0) 53 (18.9) <0.001 1205 ⁄ 61
Streptococcus pneumoniae urinary antigen detection 933 (31.6) 40 (14.3) <0.001 973 ⁄ 213
Culture of other respiratory samplesb 258 (8.7) 39 (13.9) 0.003 297 ⁄ 85
aMost patients who died did not survive long enough for a second sample to be obtained.
bOne hundred and sixty-eight positive results in 123 patients from bronchoalveolar lavage, bronchial aspiration, protected-specimen brush sampling, trans-thoracic needle
aspiration, and pleural ﬂuid samples.
Table 4. Variables associated with
length of stay in patients who were
discharged from hospitala Variable
LOS (days)
Univariate
p value
Multivariate
hazard ratio
(95% CI)
Multivariate
p valueMean Median
PSI risk class
Low-risk (classes I, II, III) 9.9 8
High-risk (classes IV, V) 13.3 11 <0.01 1.51 (1.40–1.63) <0.01
Blood cultures
Negative 11.2 9
Positive 13.3 11 <0.01 1.22 (1.00–1.49) 0.056
ICU admittance
No 11.2 9
Yes 21.1 18 <0.01 2.25 (1.82–2.78) <0.01
Empirical antibiotic
No IDSA ⁄ATS ﬁrst choice 11.6 9
IDSA ⁄ATS ﬁrst choice 11.2 9 0.34 NS 0.09
X-ray multi-lobar
No 11.2 9
Yes 13.4 11 <0.01 1.24 (1.11–1.39) <0.01
Aetiological diagnosis
No 11.4 9
Yes 11.8 9 0.207 NS 0.40
Active tobacco user
No 11.8 10
Yes 10.6 8 0.001 0.85 (0.77–0.94) <0.01
Regular consumption of alcohol
No 11.4 9
Yes 13.1 11 0.008 1.34 (1.15–1.56) <0.01
Hospital centre <0.001 NA <0.01
PSI, pneumonia severity index; LOS, length of stay; IDSA ⁄ATS, Infectious Diseases Society of America ⁄American
Thoracic Society; NS, not signiﬁcant; NA, not applicable; ICU, intensive care unit.
aTotal cases = 3233. Total cases dropped in the Cox regression model = 492 (including 280 patients who died and 34
patients who were discharged home). Cases available for analysis = 2741.
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In patients with an aetiological diagnosis,
changes in antimicrobial therapy as a conse-
quence of the microbiological report were
signiﬁcantly more frequent than in patients with-
out an aetiological diagnosis. No differences were
found for other factors resulting in a change of
antibiotic therapy, e.g., failure of treatment or the
occurrence of adverse events (Table 6).
DISCUSSION
The present study supports the hypothesis that
establishing an aetiological diagnosis for CAP and
using empirical antibiotic treatment according to
clinical practice guidelines for CAP are associated
with reduced late mortality in hospitalised
patients with CAP, even after adjusting for
potential confounders. An aetiological diagnosis
is also a factor favourable for overall mortality.
In the present study, the diagnostic procedures
were not the same for patients who died and
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Fig. 1. Mortality over time.
Table 5. Variables associated with early (£2 days), late (‡3 days) and total mortalitya
Variable
% mortality Multivariate OR (95% CI) Multivariate p value
Early Late Total Early Late Total Early Late Total
PSI risk class
Low-risk (classes I, II, III) 0.2 1.9 2.1 13.0 (4.0–42.6) 6.1 (4.0–9.3) 7.3 (4.9–10.9) <0.01 <0.01 <0.01
High-risk (classes IV, V) 3.1 12.1 15.2
Blood cultures
Negative 1.7 6.6 8.2 – 3.8 (1.9–7.6) 3.4 (1.7–6.5) NS <0.01 <0.01
Positive 1.9 15.5 17.4
ICU admittance
No 1.4 5.9 7.3 4.6 (2.1–9.9) 6.7 (4.4–10.5) 7.7 (5.0–11.7) <0.01 <0.01 <0.01
Yes 6.8 28.4 35.2
Empirical antibiotic
No IDSA ⁄ATS ﬁrst choice 1.2 8.1 9.3 – 0.6 (0.5–0.8) 0.7 (0.5–0.9) NS <0.01 0.02
IDSA ⁄ATS ﬁrst choice 1.7 5.8 7.4
X-ray multi-lobar
No 1.2 6.0 7.3 2.8 (1.4–5.5) 2.0 (1.4–2.9) 2.3 (1.6–3.3) <0.01 <0.01 <0.01
Yes 4.1 12.4 16.5
Aetiological diagnosis
No 1.8 7.2 8.9 – 0.5 (0.3–0.8) 0.5 (0.3–0.8) NS <0.01 <0.01
Yes 1.3 6.4 7.7
Active tobacco user
No 1.9 7.9 9.9 – 0.5 (0.3–0.9) 0.5 (0.3–0.8) NS 0.01 <0.01
Yes 0.6 3.9 3.9
Regular consumption of alcohol
No 1.7 7.0 8.6 – – – NS NS NS
Yes 1.9 7.0 8.9
Hospital centre – – – – NA – NS 0.048 NS
PSI, pneumonia severity index; IDSA ⁄ATS, Infectious Diseases Society of America ⁄American Thoracic Society; NS, not signiﬁcant; NA, not applicable; ICU, intensive care unit.
aNo. of selected cases = 3233. No. of rejected cases in the multivariate analysis = 212 (196 cases that received different antibiotics from those considered in the study and 18
cases in which radiological extension of the chest X-ray was not recorded). No. of cases included in the analysis = 3021.
Table 6. Reasons for a change in antibiotic therapy, showing the association with an aetiological diagnosis and
antimicrobial therapy at admission (n = 3021)a
Cause of change in antibiotic therapy
Aetiological diagnosis Empirical antibiotic IDSA ⁄ATS ﬁrst choice
No (n = 2322) Yes (n = 699) p value No (n = 1293) Yes (n = 1728) p value
Failure of treatment 176 (7.6) 62 (8.9) NS 103 (8.0) 135 (7.8) NS
Microbiological report 41 (1.7) 213 (30.5) <0.001 106 (8.2) 148 (8.6) NS
Adverse events 57 (2.5) 11 (1.6) NS 25 (1.9) 43 (2.5) NS
IDSA ⁄ATS, Infectious Diseases Society of America ⁄American Thoracic Society; NS, not signiﬁcant.
aNumber of patients included in the multivariate analysis.
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those who survived. In accordance with IDSA and
ATS guidelines [2,10], two pre-treatment blood
cultures, as well as a Gram’s stain and culture of
expectorated sputum (the ATS recommends a
Gram’s stain and culture of sputum only if a
drug-resistant pathogen or an organism not cov-
ered by the usual empirical therapy is suspected),
should be performed. Both guidelines recom-
mend that Legionella urinary antigen should be
determined, at least for patients with severe CAP.
In the present study, only 48.6% of the patients
had pre-treatment blood cultures taken. However,
this proportion was the same for those who died
and those who survived. Other microbiological
studies, including Gram’s stain and culture of
expectorated sputum, pneumococcal urinary anti-
gen determination and Legionella urinary antigen
determination, were performed more frequently
for survivors than for patients who died, despite
the fact that, in the case of Legionella urinary
antigen, guidelines recommend this procedure,
especially for patients with severe CAP.
A large inter-hospital variability in LOS has
been demonstrated previously, and this has been
reported to be associated with factors such as PSI
risk class, complications during hospitalisation,
admission to an ICU, need for oxygen adminis-
tration, and transfer to a long-term care facility
[11,12]. In the present study, LOS varied mark-
edly among centres, with a minimum of 7.8 days
in centre 8 and a maximum of 17.3 days in
centre 10. In the multivariate Cox regression
model, LOS increased signiﬁcantly with a PSI
high-risk class, the presence of positive blood
cultures, admission to an ICU, multi-lobar X-ray
involvement, and regular alcohol consumption.
Likewise, the individual hospital was an inde-
pendent factor associated with LOS. In contrast,
and surprisingly, active use of tobacco was
associated with a reduced LOS. It has been
reported previously that alcohol abuse increases
the incidence and severity of bacterial pneumonia
by depressing the inﬂammatory response to
infection [13,14], but not the rate of mortality
[15]. There are very few studies that have assessed
the inﬂuence of smoking tobacco on LOS, but a
recent study by Marrie et al. [16] found that
cigarette smoking was a factor predictive of ICU
admission.
There are several factors that inﬂuence mortal-
ity among hospitalised patients with CAP. Most
of these can be deﬁned as ‘patient factors’ that
cannot be modiﬁed. In the present study, PSI
high-risk classiﬁcation, bacteraemia, ICU admis-
sion and multi-lobar X-ray involvement were all
associated with increased overall mortality,
whereas the establishment of an aetiological
diagnosis, antimicrobial therapy according to
IDSA ⁄ATS guidelines, and active use of tobacco
were associated with decreased overall mortality.
When early mortality and late mortality were
analysed separately, PSI high-risk classiﬁcation,
admission to an ICU and multi-lobar X-ray
involvement were associated independently with
both early and late mortality. In contrast, empir-
ical antibiotic treatment according to IDSA ⁄ATS
guidelines, an aetiological diagnosis and active
use of tobacco were associated with reduced late
mortality, whereas a positive blood culture was
associated with increased late mortality.
Several studies have revealed that the use of
antimicrobial therapy in accordance with guide-
lines seems to reduce 30-day mortality among
patients hospitalised with pneumonia, especially
severe CAP [17–19]. In the present study, empir-
ical antibiotic treatment at admission according to
IDSA ⁄ATS guidelines was associated with
reduced late mortality, although no association
was found for early and overall mortality,
probably because of the diluting effect of early
mortality. This agrees with the results of Marrie
et al. [5], who reported that treatment with
levoﬂoxacin alone or with cefuroxime plus
azithromycin was associated with decreased late
mortality, but not with early mortality. Similarly,
it has been suggested [20] that antibiotic therapy
is less likely to have an impact in the ﬁrst few
days. The present study was retrospective, so it
cannot be stated conclusively that the use of
empirical antimicrobial therapy according to
IDSA ⁄ATS guidelines has a signiﬁcant impact
on survival. However, there is no reason to
believe that adherence or non-adherence to guide-
lines is based on the severity of the illness or on
some other factor that may inﬂuence mortality.
A major ﬁnding in the present study was the
association of an aetiological diagnosis as an
independent negative factor with overall and late
mortality, but not with early mortality. To our
knowledge, this is the ﬁrst evidence for the
potential impact of an aetiological diagnosis on
overall and late mortality. Other retrospective
studies have shown that outcome in patients with
severe illness is not improved by establishing a
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speciﬁc aetiological diagnosis [21–24]. However,
these studies were not designed speciﬁcally to test
this hypothesis. Some prospective studies have
concluded that identiﬁcation of the pathogen does
not affect clinical outcome [25–28], although it
might allow better patient management [29]. In
contrast, other studies have shown the beneﬁt of
microbiological diagnosis [30–32]. Hence, the
ﬁnding of Gram-positive diplococci following a
Gram’s stain correlated with a more rapid
response to single-agent antibiotic therapy [31].
The taking of blood cultures within 24 h of
admission has been associated with a signiﬁcant
reduction in 30-day mortality [32]. Among cases
without an aetiological diagnosis, 274 (11.8%)
patients had changes made to their initial antibi-
otic therapy as a consequence of failure of the
antibiotic treatment, the presence of adverse
events or the receipt of a microbiological report,
as compared with 286 (40.9%) patients with an
aetiological diagnosis. When the causes for the
change in antibiotic therapy were analysed sep-
arately, only the receipt of a microbiological
report was statistically signiﬁcant (1.7% vs.
30.5%; p <0.0001). Overall, 31.2% of patients with
an aetiological diagnosis had changes made in
their treatment as a result of a microbiological
report, which appears to be a higher proportion of
patients with antibiotic treatment adjustment
when compared with those without an aetiolog-
ical diagnosis. Unfortunately, the design of this
study did not allow conclusions to be drawn
regarding the protective effect on mortality of the
establishment of an aetiological diagnosis, as this
could simply be an indicator of a better process of
care in these patients.
Paradoxically, current use of tobacco had a
protective effect on mortality. Menendez et al. [33]
reported that the incidence of treatment failure in
patients with CAP was signiﬁcantly lower for
individuals with chronic obstructive pulmonary
disease, and considered that concomitant treat-
ment with steroids in these patients might be an
explanation, since some studies have reported a
beneﬁcial effect following initial steroid treatment
[34]. A retrospective study of patients with bac-
teraemic pneumococcal pneumonia found that
tobacco exposure was a strong independent risk-
factor for invasive disease among immunocom-
petent, non-elderly adults. Further studies are
needed to clarify the inﬂuence of tobacco use on
mortality and LOS in CAP.
The main strengths of the present study were
the large sample size, the large number of vari-
ables collected from the clinical records, and the
accuracy of the data following the efforts of
independent reviewers, who monitored 100% of
the data of all patients’ charts. However, the study
has several limitations. First, as with any retro-
spective study, there is potential for residual
confounding; the results should therefore be
extrapolated with caution, since retrospective
studies are not suitable for hypothesis testing,
but only for exploratory analyses. Second, the
quality of the data analysed is naturally related to
the quality of the medical and nursing records.
Nevertheless, the study enabled an audit-like
revision to be performed in each participating
hospital.
The main ﬁnding of this study was that a
number of factors were associated independently
with prolonged hospital stay and mortality. More
speciﬁcally, compliance with the IDSA ⁄ATS
guidelines for empirical therapy had a signiﬁcant
impact on late and global mortality, as well as the
establishment of an aetiological diagnosis.
In conclusion, the present study suggests that
early mortality in CAP is associated mostly with a
poorer baseline clinical status of the patient,
which also determines the failure to respond to
antibiotic therapy. Conversely, late mortality
seems to be related closely to microbiological
variables, and therefore an aetiological diagnosis
and compliance with appropriate therapeutic
guidelines are more important in determining
the outcome in such cases.
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